このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Biocartis Group マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Roger Moody

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	1.2yrs
CEOの所有権	n/a
経営陣の平均在職期間	3.9yrs
取締役会の平均在任期間	6.4yrs

経営陣の近況

Recent updates

Investors Give Biocartis Group NV (EBR:BCART) Shares A 31% Hiding

Jun 17

Analysts Have Been Trimming Their Biocartis Group NV (EBR:BCART) Price Target After Its Latest Report

Feb 27

What Type Of Returns Would Biocartis Group's(EBR:BCART) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Jul 28

CEO（最高経営責任者

Roger Moody

1.2yrs

在職期間

Mr. Roger Moody is Chief Executive Officer of Biocartis Group NV from April 24, 2023. Mr. Moody has experience in the technology and healthcare industry and brings a unique combination of deep knowledge of...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Piet Houwen	Chief Operating Officer	5.2yrs	データなし	データなし
Roger Moody	Chief Executive Officer	1.2yrs	データなし	データなし
George Cardoza	CFO & Head of Service Delivery	less than a year	データなし	データなし
Benoit Devogelaere	Chief Technology Officer	6.5yrs	データなし	データなし
Geert Maertens	Chairman of Scientific Advisory Board & Chief Scientific Officer	no data	データなし	データなし
Renate Degrave	Head of IR & Corporate Communications	no data	データなし	データなし
Erik Vossenaar	Senior Vice-President of Corporate Development & Strategy	less than a year	データなし	データなし
Susy Spruyt	Head of People & Organization	9.4yrs	データなし	データなし
Erwin Sablon	Head of R&D and Alliance Management	11.8yrs	データなし	データなし
Reginald Van Genechten	Head of Manufacturing & Supply Chain	8.3yrs	データなし	データなし
Sarah Baudenelle	Head of Operations & On-Market Product Support	less than a year	データなし	データなし
Karlien Hermans	Head of Quality & Regulatory	2.7yrs	データなし	データなし

3.9yrs

平均在職期間

56yo

平均年齢

経験豊富な経営陣: BCARTの経営陣は経験豊富であると考えられます ( 3.9年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Geert Maertens	Chairman of Scientific Advisory Board & Chief Scientific Officer	no data	データなし	データなし
Christian Reinaudo	Independent Director	6.1yrs	€84.00k	データなし
Herman Verrelst	Independent Chairman of the Board	6.8yrs	€436.78k	データなし
Jean-Louis Vincent	Member of Scientific Advisory Board	no data	データなし	データなし
Ann-Christine Sundell	Non Executive Independent Director	6.4yrs	€47.50k	データなし
Pasi Antero Janne	Member of Scientific Advisory Board	no data	データなし	データなし
Alberto Bardelli	Member of Scientific Advisory Board	no data	データなし	データなし
Eric Cutsem	Member of Scientific Advisory Board	no data	データなし	データなし
Josep Tabernero Caturla	Member of Scientific Advisory Board	no data	データなし	データなし
Bert Niesters	Member of Scientific Advisory Board	no data	データなし	データなし
Luc Gijsens	Non-Executive Independent Director	6.4yrs	€49.50k	データなし
Michael Press	Member of Scientific Advisory Board	no data	データなし	データなし

6.4yrs

平均在職期間

66yo

平均年齢

経験豊富なボード: BCARTの取締役会は経験豊富であると考えられます ( 6.4年の平均在任期間)。

Biocartis Group マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Biocartis Appoints New Medical Advisory Board (Mab) of Renowned Practice Leaders

Biocartis Group NV Appoints George Cardoza as Chief Financial Officer, Effective 7 August 2023

Biocartis Group NV Announces Resignation of Jean-Marc Roelandt as CFO

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

New minor risk - Financial data availability

Biocartis Group NV Presents Four Abstracts Showing Excellent Data for Idylla at European Society of Molecular Oncology Congress

First half 2023 earnings released

Biocartis Appoints New Medical Advisory Board (Mab) of Renowned Practice Leaders

Biocartis Group NV to Report First Half, 2023 Results on Sep 26, 2023

Biocartis Group NV Appoints George Cardoza as Chief Financial Officer, Effective 7 August 2023

Investors Give Biocartis Group NV (EBR:BCART) Shares A 31% Hiding

New major risk - Share price stability

Biocartis Group NV Announces Resignation of Jean-Marc Roelandt as CFO

Full year 2022 earnings released: €0.79 loss per share (vs €1.24 loss in FY 2021)

Full year 2022 earnings released: €0.79 loss per share (vs €1.24 loss in FY 2021)

Biocartis Group NV Announces the Launch of the First Assay Developed With the New Idylla™ Flex Technology

Biocartis Group NV has completed a Follow-on Equity Offering in the amount of €25.107699 million.

Price target decreased to €4.75

Insufficient new directors

Biocartis Group NV Announces New Idylla™ EGFR Study Shows Reduction of Time-To-Treatment by 48% for Lung Cancer Patients

Biocartis Group NV Announces New Idylla™ EGFR Study Shows Reduction of Time-To-Treatment by 48% for Lung Cancer Patients

Biocartis Group NV to Report Q1, 2023 Results on Apr 20, 2023

First half 2022 earnings released: EPS: €0 (vs €0.65 loss in 1H 2021)

Biocartis Group NV Provides Earnings Guidance for 2022

Biocartis Group NV Obtains ISO 27001 Certification for Information Security Management

Biocartis Group NV Announces Launch of its Rapid CE-marked IVD Idylla GeneFusion Panel for Fast Treatment Decisions in Lung Cancer

Biocartis Group NV announces New Study Led by Memorial Sloan Kettering Cancer Center (NY, US) Shows Idylla™ Genefusion Assay Enables More Rapid Screening of Targetable Fusions Compared to Routine Methods

Price target decreased to €4.75

Insufficient new directors

Biocartis Group NV Reconfirms Earnings Guidance of 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Analysts Have Been Trimming Their Biocartis Group NV (EBR:BCART) Price Target After Its Latest Report

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Biocartis Group NV Provides Earnings Guidance for the Year 2022

Biocartis Group NV Announces Publication of Large New Study Comparing the Difference in Turnaround Time Between In-House Automated Rapid Pcr3-Based EGFR Analysis and Next-Generation Sequencing

Price target decreased to €6.50

Insufficient new directors

Biocartis’ Idylla™ SARS-CoV-2 Testing Successfully Detects Omicron Variant

Biocartis Group NV Announces Restart of Its High-Throughput Cartridge Manufacturing Line

Biocartis Group NV Receives EUR 1.4 Million Grant to Support Development of New Idylla™ Technology

Biocartis Group NV Reconfirms Production Guidance of 2021

Full year 2020 earnings released: €1.11 loss per share (vs €1.14 loss in FY 2019)

We Think Biocartis Group (EBR:BCART) Has A Fair Chunk Of Debt

Full year 2020 earnings released: €1.11 loss per share (vs €1.14 loss in FY 2019)

New 90-day low: €4.41

Revenue and earnings beat expectations

What Kind Of Shareholders Own Biocartis Group NV (EBR:BCART)?

What We Learned About Biocartis Group's (EBR:BCART) CEO Compensation

Biocartis Group NV Announces Ten Idylla™ Studies to be Published at Virtual AMP (US) Annual Meeting

Biocartis Group NV Announces Publication of Large Multi-Center Comparison Study with Idylla™ MSI Assay

Biocartis Group NV to Report Q3, 2021 Results on Nov 10, 2021

Biocartis and Geneprodx to Collaborate on Fully Automated Thyroidprint Test on Idylla

Biocartis Group NV Announces Partnership with Endpoint Health to Develop Novel Companion Diagnostic in Critical Illness

Price target lowered to €7.75

New 90-day low: €4.16

Biocartis Group Nv Announces Market Release of Septicyte® Rapid Test on Idylla™

First half earnings released

Biocartis Group NV to Report Fiscal Year 2020 Final Results on Apr 01, 2021

New 90-day high - €5.02

What Can We Learn About Biocartis Group's (EBR:BCART) CEO Compensation?

New 90-day high - €5.01

What Type Of Returns Would Biocartis Group's(EBR:BCART) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24